Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Imperial Brands to repurchase £625m in second buyback tranche

(Sharecast News) - Tobacco giant Imperial Brands said on Thursday that it will repurchase up to £625.0m shares as part of its ongoing multi-year buyback programme. Imperial Brands said the purpose of its share buyback programme was to deliver "a material reduction" in its capital base over time, which it expects, together with its "progressive dividend policy", to provide an "ongoing source of shareholder returns".

The FTSE 250-listed group stated its share repurchase programme was in line with its unchanged capital allocation framework and consistent with its policy of distributing surplus capital to shareholders, while maintaining year-end leverage at the lower end of its 2.0-2.5x net debt to underlying earnings target range.

Imperial noted that the first £625.0m tranche of the current share repurchase programme has already been completed and said in order to execute the second tranche of the programme, it has entered into an irrevocable and non-discretionary arrangement with Barclays Capital Securities to repurchase up to £625.0m of its shares before 29 October.

"Under this arrangement, Barclays will act as riskless principal and will make decisions under the programme independently from the company. Purchases may continue during any closed period to which the company is subject. The purpose of the share repurchase programme is to reduce the share capital of Imperial Brands. All shares repurchased as part of this arrangement will be cancelled," said Imperial.

As of 1120 BST, Imperial Brands shares were up 0.23% at 3,081.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.